JP2019534044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534044A5 JP2019534044A5 JP2019545717A JP2019545717A JP2019534044A5 JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5 JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022087695A JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419157P | 2016-11-08 | 2016-11-08 | |
| US62/419,157 | 2016-11-08 | ||
| PCT/US2017/060122 WO2018089293A2 (en) | 2016-11-08 | 2017-11-06 | Anti-pd1 and anti-ctla4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Division JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534044A JP2019534044A (ja) | 2019-11-28 |
| JP2019534044A5 true JP2019534044A5 (enExample) | 2021-02-12 |
Family
ID=60409406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545717A Pending JP2019534044A (ja) | 2016-11-08 | 2017-11-06 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11124570B2 (enExample) |
| EP (1) | EP3538137A2 (enExample) |
| JP (2) | JP2019534044A (enExample) |
| CN (2) | CN110312523B (enExample) |
| AU (1) | AU2017356860A1 (enExample) |
| CA (1) | CA3042249A1 (enExample) |
| WO (1) | WO2018089293A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475627B (zh) * | 2016-05-26 | 2023-01-06 | 齐鲁普吉湾生物治疗公司 | 抗体混合物 |
| CN110312523B (zh) | 2016-11-08 | 2024-04-26 | 齐鲁皮吉特湾生物治疗有限公司 | 抗pd1和抗ctla4抗体 |
| IL284421B2 (en) * | 2018-12-28 | 2025-05-01 | Transgene | M2-defective poxvirus |
| EP3969476A1 (en) | 2019-03-04 | 2022-03-23 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| AU2020336440A1 (en) | 2019-08-30 | 2022-03-24 | Qilu Puget Sound Biotherapeutics Corporation | Anti-CD20 antibodies, anti-CD37 antibodies, and mixtures thereof |
| WO2021225378A1 (ko) * | 2020-05-06 | 2021-11-11 | 고려대학교 산학협력단 | Pd-l1 친화도가 증가된 pd-1 변이체 |
| CN111875697B (zh) * | 2020-08-03 | 2021-10-01 | 杭州皓阳生物技术有限公司 | 一种包含肽标签的融合蛋白 |
| CN117337304A (zh) * | 2021-02-18 | 2024-01-02 | 齐鲁普吉湾生物治疗公司 | 抗pd1抗体和抗ctla4抗体的联合 |
| CN118660720A (zh) * | 2022-02-22 | 2024-09-17 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN119255817A (zh) * | 2022-03-28 | 2025-01-03 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN118946366A (zh) * | 2022-04-13 | 2024-11-12 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| US20250313643A1 (en) * | 2022-06-07 | 2025-10-09 | Unm Rainforest Innovations | Humanized non-opioid composition and therapies for pain management |
| CN119300862A (zh) * | 2022-06-28 | 2025-01-10 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| CN119300863A (zh) * | 2022-06-30 | 2025-01-10 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2025113598A1 (zh) * | 2023-12-01 | 2025-06-05 | 齐鲁制药有限公司 | 稳定的混合抗体的药物组合物 |
| WO2025228542A1 (en) | 2024-05-03 | 2025-11-06 | Genmab B.V. | Method for co-expression of a plurality of antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993016719A2 (en) | 1992-02-26 | 1993-09-02 | Allergan, Inc. | Use of platelet derived growth factor in ophthalmic wound healing |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP3553085A1 (en) * | 1998-12-23 | 2019-10-16 | Pfizer Inc | Human momoclonal antibodies to ctla-4 |
| DK1212422T3 (da) * | 1999-08-24 | 2007-07-02 | Medarex Inc | Humane CTLA-4-antistoffer og anvendelserne deraf |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| CN104945508B (zh) * | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| WO2009100140A1 (en) * | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| US20090311187A1 (en) * | 2008-05-29 | 2009-12-17 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the Co-stimulatory pathway |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| EP2488553B1 (en) * | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Cancer treatment |
| JP5995851B2 (ja) | 2010-10-18 | 2016-09-21 | メディアファーマ エス． アール． エル．Ｍｅｄｉａｐｈａｒｍａ Ｓ． Ｒ． Ｌ． | ＥｒｂＢ３結合抗体 |
| IN2013MN01438A (enExample) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
| CN202105787U (zh) | 2011-06-03 | 2012-01-11 | 杨自强 | 糠粞分离机 |
| TWI835048B (zh) | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP2975061A4 (en) | 2013-03-13 | 2017-03-01 | Ibentrus Inc. | Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor |
| SI3081576T1 (sl) * | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| MA44082A (fr) * | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| CN110312523B (zh) | 2016-11-08 | 2024-04-26 | 齐鲁皮吉特湾生物治疗有限公司 | 抗pd1和抗ctla4抗体 |
-
2017
- 2017-11-06 CN CN201780069181.5A patent/CN110312523B/zh active Active
- 2017-11-06 CA CA3042249A patent/CA3042249A1/en active Pending
- 2017-11-06 EP EP17801203.5A patent/EP3538137A2/en active Pending
- 2017-11-06 US US16/347,554 patent/US11124570B2/en active Active
- 2017-11-06 CN CN202410423333.9A patent/CN118480125A/zh active Pending
- 2017-11-06 AU AU2017356860A patent/AU2017356860A1/en not_active Abandoned
- 2017-11-06 WO PCT/US2017/060122 patent/WO2018089293A2/en not_active Ceased
- 2017-11-06 JP JP2019545717A patent/JP2019534044A/ja active Pending
-
2021
- 2021-09-16 US US17/477,525 patent/US12037397B2/en active Active
-
2022
- 2022-05-30 JP JP2022087695A patent/JP7455897B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534044A5 (enExample) | ||
| ES2777603T3 (es) | Anticuerpos PD-L1 ("ligando de muerte programada 1") | |
| RU2425841C2 (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
| JP2020516240A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| JP2017535257A5 (enExample) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| CN102753195A (zh) | 用于增强抗肿瘤抗体疗法的方法 | |
| JP2018532383A5 (enExample) | ||
| JP2025065211A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| JP2019528683A5 (enExample) | ||
| CN111183159A (zh) | 靶向cd137的抗体及其使用方法 | |
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| AU2020207664A1 (en) | Antibodies specific to human Nectin-2 | |
| CN113412124A (zh) | Baff-r双特异性t细胞衔接子抗体 | |
| JPWO2019165340A5 (enExample) | ||
| CN113501879B (zh) | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 | |
| IL277899B1 (en) | Methods and compositions for treating yellow fever | |
| JPWO2020144697A5 (enExample) | ||
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| AU2015271978B2 (en) | Treatment for neoplastic diseases |